Clearstead Trust LLC Has $786,000 Holdings in Pfizer Inc. (NYSE:PFE)

Clearstead Trust LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 1.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,104 shares of the biopharmaceutical company’s stock after selling 420 shares during the period. Clearstead Trust LLC’s holdings in Pfizer were worth $786,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Edgestream Partners L.P. increased its position in Pfizer by 1,704.3% in the 2nd quarter. Edgestream Partners L.P. now owns 157,967 shares of the biopharmaceutical company’s stock worth $4,420,000 after purchasing an additional 149,212 shares during the last quarter. Pekin Hardy Strauss Inc. increased its position in Pfizer by 8.4% in the 2nd quarter. Pekin Hardy Strauss Inc. now owns 27,095 shares of the biopharmaceutical company’s stock worth $758,000 after purchasing an additional 2,090 shares during the last quarter. Moors & Cabot Inc. increased its holdings in shares of Pfizer by 18.7% during the 2nd quarter. Moors & Cabot Inc. now owns 451,182 shares of the biopharmaceutical company’s stock valued at $12,624,000 after acquiring an additional 71,082 shares during the last quarter. Excalibur Management Corp increased its holdings in shares of Pfizer by 1.9% during the 2nd quarter. Excalibur Management Corp now owns 164,336 shares of the biopharmaceutical company’s stock valued at $4,598,000 after acquiring an additional 3,090 shares during the last quarter. Finally, Lmcg Investments LLC increased its holdings in shares of Pfizer by 1.1% during the 2nd quarter. Lmcg Investments LLC now owns 51,777 shares of the biopharmaceutical company’s stock valued at $1,449,000 after acquiring an additional 543 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE stock opened at $30.07 on Tuesday. The stock has a 50 day moving average of $29.26 and a two-hundred day moving average of $28.15. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $34.12. The company has a market capitalization of $170.40 billion, a P/E ratio of -501.08, a P/E/G ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.59%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PFE. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday. UBS Group increased their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.